"There is also a movement toward limiting the loss of healthy lung tissue to lung cancer operations," Dr. Jablons added, "but there is concern that important prognostic information currently used in conventional staging might be lost with less radical surgery. Pervenio™ has been shown to provide even more accurate information about prognosis and would therefore enable equal or even better clinical management decisions with lung-sparing operations."
Pervenio™ Lung RS is available through the
Life Technologies' Clinical Services Lab, which is licensed in all 50 U.S. states. Life Technologies also plans to make Pervenio™ Lung RS available outside of
the United States
, so the test can be broadly deployed on Life Technologies' regulated platforms, including the 7500 Fast Dx for qPCR.
The study, titled "Ability of a Prognostic Assay to Identify Patients at High Risk of Mortality Despite Small, Node-Negative Lung Tumors," was supported by private endowments to the UCSF Thoracic Oncology Laboratory and by Pinpoint Genomics, which Life Technologies acquired in
For more information, please visit
. To order Pervenio™ Lung RS, call the Life Technologies Clinical Services Lab at 1-888-734-8588
JAMA, Vol. 308 No. 16, pp. 1629-1631,
October 24, 2012
The Lancet, Vol. 379 No. 9818, pp. 823-832,
Mar 03, 2012
About Life Technologies
Life Technologies Corporation
(NASDAQ: LIFE) is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today's most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum with more than 50,000 products for agricultural biotechnology, translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent™, Applied Biosystems®, Invitrogen™, GIBCO®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of
in 2011. Visit us at our website:
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Contact
SOURCE Life Technologies Corporation